Rituximab biosimilar (Biosidus)

利妥昔单抗生物类似药 (Biosidus)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRituximab biosimilar (Biosidus)

Drug Alias Name利妥昔单抗生物仿制药 (Biosidus)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4]

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsHematologic Neoplasms

Approved Indications in ChinaN/A

Original Approved Country/TerritoryArgentina

Original Approved Date2013/06/01

Country/TerritoryArgentina

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaN/A

Originator CompaniesBiosidus

China Registration ClassN/A

Develop Information

Active CompaniesBiosidus

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeL01XC02